2014-07-15T11:49:50-07:00 2013-12-31 990 2013-01-01 236434390 THE WISTAR INSTITUTE OF ANATOMY & BIOLOGY WIST 2158989910 3601 Spruce Street Philadelphia PA 191044265 Joseph G Trainor Chief Financial Officer 2154956922 2014-07-15 2013 2016-02-25 16:41:14Z Joseph G Trainor 3601 Spruce Street Philadelphia PA 191044265 139518000 0 X www.wistar.org X 1892 PA Biomedical research with special expertise in cancer research and vaccine development 33 33 376 49 44000 -27000 47565000 39506000 1693000 2320000 2242000 7784000 15924000 16353000 67424000 65963000 0 0 0 0 30151000 29371000 0 0 760000 31921000 28222000 62072000 57593000 5352000 8370000 193555000 246413000 50741000 86398000 142814000 160015000 Founded in 1892 as the first independent nonprofit biomedical research institute in the country, Wistar has long held the prestigious Cancer Center designation from the National Cancer Institute. Multidisclipinary research at The Wistar Institute focuses on the molecular and cellular bases of cancer, autoimmune disorders, several age-associated disorders and other serious illnesses. The Wistar Institute is dedicated to basic biomedical research-investigation driven by the desire of Wistar researchers to answer fundamental scientific questions. Throughout its history, the ability of Wistar scientists to explore their research interests has yielded new therapies, vaccines, and insights that have profoundly influenced the progress of both science and medicine. Wistar scientists are international leaders in their fields, defining the questions that must be asked and devising the tools needed to answer those questions. 0 0 44811000 0 2320000 CANCER RESEARCH - Since 1972, The Wistar Institute has been home to a National Cancer Institute-designated Cancer Center, recently ranked as "exceptional" - the highest such rating - by the NCI. The Institute enjoys a history of significant advances in cancer biology and its researchers have made fundamental public health contributions in cancer prevention, diagnosis, and therapy. Cancer Center scientists conduct research on gene expression and regulation, molecular and cellular oncogenesis , and tumor microenvironment and metastasis, and translational tumor immunology. Deciphering cancer genetics: Wistar is a national leader in illuminating how mutations in genes lead to various cancers. Its researchers study the genes, proteins, and complex signaling pathways that drive cells (and cancers). Leading the fight against melanoma: Wistar oversees one of the most prestigious melanoma research programs in the world, studying the development of the disease and pursuing treatments for advanced melanoma. Exploring the role of the tumor microenvironment: The tumor microenvironment involves the chemical conversations that occur between cancerous cells and the healthy cells that surround and support them. It is the tumor microenvironment that makes it possible for tumors to change from benign to malignant to metastatic. Targeting these cells could greatly increase the effectiveness of traditional anti-cancer treatments. IMMUNOLOGY AND VIROLOGY - The Wistar Institute remains a world leader in advancing the scientific understanding of the human immune system and its role in disease. Among its successes are vaccines against rabies, rubella and rotavirus, as well as patenting the method of producing monoclonal antibodies, a process that informs the development of many of today's targeted therapies. Working together to fight disease: Wistar researchers are collaborating with leading scientists worldwide to develop new vaccines for HIV/AIDS, Rabies, tuberculosis, malaria, and other potentially deadly diseases. Developing therapeutic vaccines against cancer: Wistar's vaccine development program also encompasses treatment vaccines against cervical cancer and other cancers caused by human papillomavirus (HPV), melanoma, and Epstein-Barr virus. A global reach: The Institute has licensed its rabies and rubella vaccine seed stock to companies in China, India, and Russia to help these countries develop affordable vaccines for their own populations. Easing the pain: Wistar Immunologists also are developing novel therapies for autoimmune diseases such as lupus and rheumatoid arthritis. TRAINING THE NEXT GENERATION OF SCIENTISTS - At the Wistar Institute, science and cancer education is our priority. Our educational and training programs cover the full spectrum from high school students and undergraduates to pre-doctoral candidates and post-doctoral researchers, with an emphasis on reaching underserved and minority populations. High School Programs: Wistar offers internships, tours, and essay contests to area high school students to stimulate and nurture their interests in science. Wistar's Summer Fellowship Program allows students to become directly involved in experimental biological research projects at the bench level. Students may work on active research projects in cancer genetics, control of tumor progression, and vaccine development. Biomedical Training Program: The Biomedical Technician Training Program prepares Community College of Philadelphia students for an exciting career in the growing field of basic and applied biomedical research. The program combines academic course work with specialized training in research laboratories at the Institute. This dual experience offers students seeking an associate's degree the opportunity to acquire the skills necessary to qualify for positions as technicians in biomedical research laboratories usually only available to graduates of four-year baccalaurate programs. Postdoctoral Programs: Postdoctoral fellows come to The Wistar Institute to carry out research under the mentorship of one of the Institute's faculty members. The postdoctoral training program emphasizes research experience and takes advantage of the cooperative interactions among the participating faculty as well as seminar courses and speaker programs. Cancer Biology Graduate Program: The cancer biology graduate degree program-jointly administered by The Wistar Institute and University of the Sciences (USciences)-trains individuals with outstanding potential for a successful academic or industrial career in cancer biology and drug development. This Ph.D. program fills a regional gap in specific training in cancer biology, and includes cutting-edge strategies in translational aspects, such as cancer prevention and therapy. 0 0 0 Not applicable 0 0 0 Not applicable 0 0 0 44811000 1 1 0 1 0 0 0 1 0 1 1 1 0 0 1 1 1 0 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 1 1 1 0 0 1 78 0 1 376 1 1 1 0 0 0 0 1 1 0 0 0 0 X 33 33 1 0 0 0 0 1 0 1 1 0 0 1 1 1 1 1 1 1 1 0 FL PA CA NJ NY AL KS MO OH AK KY OK LA OR UT GA ME AR NH VA HI MD WA CO MA NM RI WV IL MI SC WI CT MN NC MS ND TN X Joseph G Trainor CFO 2154956922 3601 Spruce Street Philadelphia PA 191044265 Helen P Pudlin Chair 4.00 0.00 X X 0 0 0 Richard Horowitz Vice Chair 4.00 0.00 X X 0 0 0 Maida Milone Secretary 2.00 0.00 X X 0 0 0 Elizabeth McKee Anderson Trustee 1.00 0.00 X 0 0 0 Van Billet Trustee 1.00 0.00 X 0 0 0 Robert S Blank Trustee 1.00 0.00 X 0 0 0 Douglas D Briggs Trustee 1.00 0.00 X 0 0 0 Ira Brind Trustee 1.00 0.00 X 0 0 0 Ronald Caplan Trustee 2.00 0.00 X 0 0 0 Brian H Dovey Trustee 1.00 0.00 X 0 0 0 Daniel Fitzpatrick Trustee 1.00 0.00 X 0 0 0 Robert A Fox Trustee 2.00 0.00 X 0 0 0 L Patrick Gage PhD Trustee 1.00 0.00 X 0 0 0 Joseph A Goldblum Trustee 1.00 0.00 X 0 0 0 Mark L Greenberg PhD Trustee 1.00 0.00 X 0 0 0 Herbert Kean MD Trustee 1.00 0.00 X 0 0 0 Faye Olivieri-Kozich Trustee 1.00 0.00 X 0 0 0 Susan S McDonald Trustee 2.00 0.00 X 0 0 0 Abraham L Morris Trustee 1.00 0.00 X 0 0 0 Albert Ominsky Esq Trustee 1.00 0.00 X 0 0 0 Arthur M Pappas Trustee 1.00 0.00 X 0 0 0 Vincent Price PhD Trustee 1.00 0.00 X 0 0 0 Samuel V Rhoads Trustee 1.00 0.00 X 0 0 0 Robert H Rock Trustee 1.00 0.00 X 0 0 0 Gerald B Rorer Trustee 1.00 0.00 X 0 0 0 Adele K Schaeffer Trustee 1.00 0.00 X 0 0 0 Paul J Schmitt Trustee 1.00 0.00 X 0 0 0 Milton S Schneider Trustee 1.00 0.00 X 0 0 0 William A Slaughter Esq Trustee 1.00 0.00 X 0 0 0 Judith Soltz Esq Trustee 1.00 0.00 X 0 0 0 David V Wachs Trustee 1.00 0.00 X 0 0 0 Daniel H Wheeler Esq Trustee 1.00 0.00 X 0 0 0 Edward Ziff PhD Trustee 1.00 0.00 X 0 0 0 Russel Kaufman MD President and CEO 65.00 0.00 X 678000 0 52000 Dario Altieri Vice President and Cancer Center Director 55.00 0.00 X 416000 0 47000 Alan Stiles Chief Operating Officer and Treasurer 55.00 0.00 X 257000 0 56000 Joseph G Trainor Chief Financial Officer 55.00 0.00 X 84000 0 11000 Elizabeth O'Brien Vice President 55.00 0.00 X 209000 0 57000 Larry Keinath Vice President 33.00 0.00 X 144000 0 30000 George Hobbs Vice President 40.00 0.00 X 134000 0 44000 Meenhard Herlyn DVM Professor 55.00 0.00 X 229000 0 53000 David Speicher PhD Professor 55.00 0.00 X 226000 0 33000 Hildegund Ertl MD Professor 55.00 0 X 222000 0 35000 Frank Rauscher PhD Professor 55.00 0.00 X 217000 0 30000 Paul Lieberman PhD Professor 55.00 0.00 X 234000 0 41000 3050000 0 489000 45 0 1 0 L F Driscoll Co LLC 9 Presidential Blvd P O Box 468 Bala Cynwyd PA 19004 Construction Management 49963000 AlliedBarton Security Services 161 Washington Street Suite 600 Conshohocken PA 19428 Security services 675000 Ballinger 833 Chestnut Street Suite 1400 Philadelphia PA 19107 Architecture Engineering Planning Interior Design 470000 ABM Mid-Atlantic Inc 420 Feheley Drive King of Prussia PA 19406 Janitorial 446000 Howson & Howson LLP 501 Office Center Drive Suite 210 Fort Washington PA 19034 Legal services 186000 12 0 0 520000 0 35368000 3618000 237000 39506000 Scientific Research 541700 2320000 2320000 0 0 0 0 0 0 2320000 1884000 0 0 1884000 0 0 0 0 16328000 0 0 16328000 0 0 79212000 35000 73347000 0 5865000 35000 5900000 0 0 5900000 112000 520000 208000 -96000 0 -96000 Sale of Specialized Services 541700 44000 0 44000 0 Rent 900099 77000 0 0 77000 0 0 0 0 121000 65963000 2320000 44000 24093000 2220000 343000 1877000 0 0 0 0 0 19619000 14218000 5145000 256000 2287000 1542000 718000 27000 3911000 2701000 1156000 54000 1334000 899000 419000 16000 0 0 0 0 508000 0 508000 0 101000 0 101000 0 138000 0 138000 0 0 0 0 0 0 0 2260000 516000 1691000 53000 92000 1000 9000 82000 426000 98000 313000 15000 563000 97000 453000 13000 0 0 0 0 5145000 2118000 3025000 2000 225000 118000 102000 5000 0 0 0 0 68000 47000 21000 0 29000 0 29000 0 0 0 0 0 5526000 5187000 305000 34000 225000 0 225000 0 Subcontracts 6938000 6938000 0 0 Lab supplies and equipment maintenance agreements 5096000 4266000 829000 1000 Allocation of Operations & Maintenance expenses reported in C 0 5319000 -5400000 81000 882000 403000 358000 121000 57593000 44811000 12022000 760000 1586000 2773000 0 12246000 23932000 13540000 14784000 11244000 0 0 0 0 0 0 57000 43000 908000 806000 147656000 46677000 51963000 100979000 66831000 66822000 33353000 37795000 0 0 0 0 141000 165000 193555000 246413000 12579000 14975000 0 0 2694000 2380000 16231000 53027000 0 0 0 0 13356000 13192000 0 0 5881000 2824000 50741000 86398000 X 83113000 103960000 35401000 28096000 24300000 27959000 142814000 160015000 193555000 246413000 X 8370000 4261000 0 0 0 4570000 X 0 1 X 1 1 1 X 41600000 49900000 68019000 47565000 39506000 246590000 41600000 49900000 68019000 47565000 39506000 246590000 246590000 11019000 14623000 20332000 16849000 18212000 81035000 0 0 0 0 0 0 53000 51000 20000 0 77000 201000 327826000 0.75220 0.7369 X Schedule A, Part II, Line 10 Rental and other miscellaneous income. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1 1 0 1 100 1 200 0 1 137700 0 0 138000 0 Schedule C, Part II-B, Line 1 The Wistar Institute engaged the services of several lobbying firms whose responsibilities are to provide government relations services to The Wistar Institute at the federal and state level with regard to both regulatory and legislative issues. Duties include monitoring and tracking legislation which may be of interest to The Wistar Institute and assisting in finding funding sources for programs. In addition, a number of Wistar staff participate in government affairs advocacy on a fairly regular basis (e.g. visits to Congressional offices to advocate for increases in the NIH budget). We also occasionally ask our board, employees or friends/volunteers to write letters or call their representatives regarding legislation that may impact Wistar. 0 0 X X X 0 13462000 1537000 2561000 0 486000 0 17074000 12084000 247000 1555000 0 424000 0 13462000 12652000 50000 -214000 0 404000 0 12084000 11357000 73000 1502000 0 280000 0 12652000 8726000 1515000 1386000 0 270000 0 11357000 0.157 0.6315 0.2115 0 0 0 162000 162000 0 49541000 22366000 27175000 0 0 0 0 0 30452000 24311000 6141000 0 67501000 0 67501000 100979000 Beneficial interest in perpetual trusts 17012000 F Alternative investments 20783000 F 37795000 0 Accrued pension expense 2283000 Interest rate swap 541000 2824000 X 75543000 4261000 0 0 5111000 9372000 66171000 0 -208000 -208000 65963000 58342000 0 0 0 749000 749000 57593000 0 0 0 57593000 Schedule D, Part III, Line 1 Collections consist of Family Memorabilia and other artifacts which is not used in the Institute's operations. Schedule D, Part III, Line 4 The Institute's collections constitute a history of medical science in Philadelphia and the history of vaccine development. The museum collections are tied to our deeds of trust and have significant historical value as Wistar was established as the first independent nonprofit biomedical research institute in the country. Schedule D, Part V, Line 4 Management determines the prudent use for the endowment funds for general purposes and to support research and training programs as specified by the various endowment programs. Schedule D, Part X, Line 2 The Institute is a not-for-profit institution which has been determined by the Internal Revenue Service to be exempt from federal income taxes under Section 501 (c)(3) of the Internal Revenue Code (IRC). The Institute accounts for uncertainties in income taxes in accordance with authoritative guidance, which prescribes a recognition threshold of more-likely-than-not to be sustained upon examination by the appropriate taxing authority. Measurement of the tax uncertainty occurs if the recognition threshold has been met. Management believes that there were no tax uncertainties that met the recognition threshold for the years ended December 31, 2013 and 2012. Schedule D, Part XI, Line 2d Gain on beneficial interests in trusts $1,650,000; and pension-net gain $3,461,000. Schedule D, Part XI, Line 4b Fundraising event expenses. Schedule D, Part XII, Line 2d Fundraising event expenses $208,000 and net loss on interest rate swap $541,000. Taxin Golf Tournament 191000 166000 25000 0 13000 9000 25000 0 12000 Wistar Gala 441000 354000 87000 0 3000 6000 75000 10000 55000 0 632000 520000 112000 0 16000 15000 100000 10000 67000 208000 -96000 X X X X 0 1 X X X X 0 0 0 0 0 0 0 1 0 Russel Kaufman MD President and CEO 547000 0 80000 0 51000 0 33000 0 19000 0 730000 0 0 0 Dario Altieri Vice President and Cancer Center Director 364000 0 50000 0 2000 0 33000 0 14000 0 463000 0 0 0 Alan Stiles Chief Operating Officer and Treasurer 221000 0 10000 0 26000 0 31000 0 25000 0 313000 0 0 0 Joseph G Trainor Chief Financial Officer 79000 0 0 0 5000 0 9000 0 2000 0 95000 0 0 0 Elizabeth O'Brien Vice President 208000 0 0 0 1000 0 29000 0 28000 0 266000 0 0 0 Larry Keinath Vice President 144000 0 0 0 0 0 20000 0 10000 0 174000 0 0 0 George Hobbs Vice President 133000 0 0 0 1000 0 19000 0 25000 0 178000 0 0 0 Meenhard Herlyn DVM Professor 225000 0 0 0 4000 0 31000 0 22000 0 282000 0 0 0 David Speicher PhD Professor 225000 0 0 0 2000 0 29000 0 3000 0 259000 0 0 0 Hildegund Ertl MD Professor 222000 0 0 0 0 0 30000 0 5000 0 257000 0 0 0 Frank Rauscher PhD Professor 217000 0 0 0 0 0 29000 0 1000 0 247000 0 0 0 Paul Lieberman PhD Professor 209000 0 0 0 25000 0 27000 0 14000 0 275000 0 0 0 Schedule J, Part I, Line 1a Tax Indemnification and gross-up payments - for tuition benefits; Discretionary spending account - travel and auto allowance for CEO only; Housing allowance for CEO only; Social club dues for CEO only. All amounts included in taxable compensation. Schedule J, Part I, Line 1b Tax Indemnification and gross-up payments - yes written policy provided; Discretionary spending account, housing allowance, and social club dues are provided via employment contract with CEO. Schedule J, Part I, Line 7 Non-fixed payments in the form of bonuses approved by the board compensation committee. A Philadelphia Authority for Industrial Development 232237287 2011-07-29 55000000 Capital project financing 0 0 0 A 0 0 53027000 0 472000 0 519000 0 0 52036000 0 0 2014 0 0 0 1 A 0 0 0 0 0 0 0 0 0 1 A 0 0 1 0 1 1 Citizens Bank of Pennsylvania 10 0 0 0 0 1 A 1 Schedule K, Part II, Line 3-07/29/2011 55,000,000 Philadelphia Authority for Proceeds are drawn as construction costs are incurred. Schedule K, Part IV, Line 2c-07/29/2011 55,000,000 Philadelphia Authority for No rebate due because proceeds are drawn only as construction costs are incurred. Josh Goldblum Family member of Joseph A Goldblum, trustee. 23000 Independent Contractor 0 X 16 237000 Fair Market Value 0 0 1 1 Schedule M, Part I, Line 9 Based on the number of contributions. Schedule M, Part I, Line 32b Brokerage services Form 990, Part IV, Line 28c Supplemental information for Schedule L Part IV - Samuel V Rhoades, trustee, is Executive Vice President at Philadelphia Industrial Development Corp. which administers the Philadelphia Authority for Industrial Development, the issuing authority of the Wistar bond issue, and which acts as the intermediary between Wistar and the Commonwealth of Pennsylvania for a construction grant. Form 990, Part VI, Section A, Line 2 Daniel Wheeler (Trustee) and Robert Fox (Trustee) have a family relationship. Robert Fox (Trustee) and Richard Horowitz (Trustee) have a business relationship. Form 990, Part VI, Section A, Line 7a The Academy of Natural Sciences at Drexel University and the Wistar family have the right to designate representation to the Board of Trustees. The University of Pennsylvania approves appointments to the Board of Trustees under the Institute's founding deeds of trust. Form 990, Part VI, Section B, Line 11b The Audit Committee of the Board of Trustees reviews the 990 prior to filing the return. Also, prior to submission, the Institute posts a copy to the board's website and notifies members of its availability for their information. Form 990, Part VI, Section B, Line 12c Annually covered persons are required to submit Conflict of Interest Disclosures which are reviewed by management. Covered persons include The Wistar Institute's trustees, officers, "key employees", and next 5 most highly compensated employees. If an individual has any power or influence to approve or disapprove a contract or transaction proposed to be entered into between the Institute and any entity or person having a significant relationship to that individual, that individual has a potential conflict of interest and may not participate in the process leading to the approval or disapproval of the contract or transaction unless the underlying facts giving rise to the potential conflict of interest are disclosed and approval for participation is obtained. In the case of the Board of Trustees, no individual with a potential conflict of interest with respect to a contract or transaction or any other conflict of interest may vote to approve or disapprove the contract or transaction. Form 990, Part VI, Section B, Line 15 The organization uses the following methods to establish compensation of its key executives; Compensation committee; independent compensation consultant; and Compensation survey or study. The Executive Evaluation and Compensation Committee of the Board of Trustees documents its decisions in the minutes to its meetings. The Committee obtains an opinion from an independent compensation consultant that the proposed compensation payable to executives is reasonable. Form 990, Part VI, Section C, Line 19 The Institute's governing documents and conflict of interest policy are available on the Institute's website (www.wistar.org) The Institute's financial statements are available upon request. Form 990, Part XI, Line 9 Gain on beneficial interests in trusts $1,650,000; Pension-net gain $3,461,000; and Interest rate swap - net loss ($541,000). Issac J Wistar Foundation 3601 Spruce Street Philadelphia PA 19104 232593436 Inactive PA 501 (c) (3) PF N/A 0 Tall Cell Technology L P c/o The Connelly Fdn One Tower Bridge Suite 1450 West Conshohocken PA 19428 232811246 Licensing PA The Wistar Institute of Anatomy and Biology Related 149000 151000 0 7 1 0.9 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Tall Cell Technology L P a-iii 149000 Cash payment received representing The Wistar Institute's portion in the partnership's royalties.